Heidelberg Pharma brings Chinese investor onboard through rights issue
GlobalCapital, is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023
Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
EquityFollow-ons and Rights issues

Heidelberg Pharma brings Chinese investor onboard through rights issue

Victoria Thiele
August 31, 2022 05:08 PM
Antibodies attacking cancer cell, illustration

New shares were offered at a premium and mostly taken by an external investor in the unusual capital increase

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Follow-ons and Rights issues Asia Follow-ons and Rights IssuesGermanyEquityHealth and Biotech
VT
Victoria Thiele
Senior Reporter - CLOs
Contact